Last reviewed 2026-04-20 · How we verify

GOSOGLIPTIN

FDA-approved approved Small molecule Quality 6/100

At a glance

Generic name	GOSOGLIPTIN
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved
First approval	2016

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Efficacy and Safety of Gosogliptin as Monotherapy and in Combination With Metformin vs. Vildagliptin as Monotherapy and in Combination With Metformin in Drug-naive Type 2 Diabetic Patients. (PHASE3)
A Study to Evaluate the Blood Levels, Safety, and Tolerability of PF-00734200 in Subjects With Impaired Kidney Function and Normal Kidney Function (PHASE1)
Effect of PF-00734200 in Subjects With Type 2 Diabetes (PHASE2)
12 Week Study Of PF-00734200 For The Treatment Of Type 2 Diabetes Mellitus In Subjects Treated With Metformin (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.gov	Trial enrolment, design, endpoints, results